Sector Chart Gilead Sciences, Inc.

GILD

US3755581036

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Sector Other Pharmaceuticals

	Capi.	Sales growth	Profitability	Finances	EV / Sales	P/E
GILEAD SCIENCES, INC.	149B
ELI LILLY AND COMPANY	920B
JOHNSON & JOHNSON	510B
ABBVIE INC.	395B
ROCHE HOLDING AG	340B
ASTRAZENECA PLC	278B

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
120.40 ^USD	-2.28%		-0.68%	+30.35%

12-12	Arcus Biosciences, Inc. Provides Update on Phase 3 Star-221 Study and Concentrates Its R&D Investment on Cas Datifan and Emerging Inflammation and Immunology Portfolio	CI
12-12	Arcus, Gilead to Discontinue Phase 3 Trial of Potential Cancer Treatment -- Update	DJ

Sector Chart Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Sector Other Pharmaceuticals